The Centers for Medicare & Medi caid Services (CMS) has released a proposed decision memo that suggests it will cover the cost of sipuleucel-T (Provenge), the immunotherapy vaccine approved in April 2010 for men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer, for on-label use. CMS contractors will have discretion as to whether they will cover it for off-label use.
Cancer treatment–induced diarrhea (CTID) occurs in 50% to 80% of patients receiving chemo therapy and 50% of patients undergoing radiotherapy. Older patients, women, patients on an irinotecan-containing regimen, and patients treated in the adjuvant setting are at higher risk of CTID, reported Kelly Markey, PharmD, BCOP. Markey is a clinical pharmacist with the gastrointestinal tumor program at Moffitt Cancer Center in Tampa, Florida, and discussed CTID at the annual meeting of the Hematology/Oncology Pharmacy Association.
Every year, the demand for healthcare services grows in the United States and more responsibilities for providing that care are shifted to nurses. While NursingSchool.org reports that the country has at least 5.5 million nurses and nursing aides, this number is not nearly high enough to keep pace with the rising number of patients. The resulting shortage leaves many nurses feeling overworked and underpaid.
Read More ›
If you are attending the 2011 Oncology Nursing Society Annual Con gress in Boston, we would like to hear from you. Email editorial@greenhillhc.com and share your experiences at the conference in 500 words or fewer. We will select the best emails to published in an up coming issue of The Oncology Nurse-APN/PA and on our Website.
The National Cancer Institute set out to answer this question last year and published results of their investigation in the January 2011 issue of the Journal of the National Cancer Institute. The study’s authors point to flaws in previous cancer cost estimates, many of which did little more than take figures from 15 years ago and adjust them for inflation.
APP Pharmaceuticals has issued a voluntary recall of 5 lots of irinotecan hydrochloride injection (Camptosar) as a precautionary measure. No adverse events related to the recalled products have been reported. The following lots have been recalled:
Despite aggressive campaigns to educate Americans on the lifethreatening risks of smoking, nearly 500,000 people die each year in the United States from smoking-related illness, according to a recent study in Epidemiology. Even patients with smoking- related cancers have trouble quitting, with about two-thirds of patients with lung cancer continuing to smoke.
To sign up for our newsletter or print publications, please enter your contact information below.
